Trade Day One Biopharmaceuticals - DAWN CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Trading сonditions
| Spread | 0.08 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Day One Biopharmaceuticals Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Key Stats
| Prev. Close* | 15.71 |
| Open* | 15.7 |
| 1-Year Change* | 25.1% |
| Day's Range* | 14.47 - 15.94 |
| 52 wk Range | 9.67-23.25 |
| Average Volume (10 days) | 432.34K |
| Average Volume (3 months) | 13.20M |
| Market Cap | 1.20B |
| P/E Ratio | -100.00K |
| Shares Outstanding | 87.04M |
| Revenue | N/A |
| EPS | -2.30 |
| Dividend (Yield %) | N/A |
| Beta | -100.00K |
| Next Earnings Date | N/A |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 18, 2024 | 15.71 | 0.92 | 6.22% | 14.79 | 16.08 | 14.60 |
| Apr 17, 2024 | 14.81 | 0.23 | 1.58% | 14.58 | 15.19 | 14.51 |
| Apr 16, 2024 | 14.57 | 0.88 | 6.43% | 13.69 | 14.68 | 13.67 |
| Apr 15, 2024 | 13.80 | 0.03 | 0.22% | 13.77 | 13.93 | 13.64 |
| Apr 12, 2024 | 13.73 | -0.20 | -1.44% | 13.93 | 14.11 | 13.53 |
| Apr 11, 2024 | 14.02 | -0.36 | -2.50% | 14.38 | 14.74 | 13.94 |
| Apr 10, 2024 | 14.37 | 0.50 | 3.60% | 13.87 | 14.52 | 13.70 |
| Apr 9, 2024 | 14.34 | 0.39 | 2.80% | 13.95 | 14.34 | 13.87 |
| Apr 8, 2024 | 13.89 | -0.69 | -4.73% | 14.58 | 14.69 | 13.83 |
| Apr 5, 2024 | 14.50 | 0.53 | 3.79% | 13.97 | 14.68 | 13.73 |
| Apr 4, 2024 | 14.16 | -1.37 | -8.82% | 15.53 | 15.80 | 14.12 |
| Apr 3, 2024 | 15.57 | -0.03 | -0.19% | 15.60 | 15.81 | 15.45 |
| Apr 2, 2024 | 15.78 | 0.11 | 0.70% | 15.67 | 15.94 | 15.37 |
| Apr 1, 2024 | 16.14 | -0.19 | -1.16% | 16.33 | 16.33 | 15.82 |
| Mar 28, 2024 | 16.47 | 0.65 | 4.11% | 15.82 | 16.86 | 15.69 |
| Mar 27, 2024 | 15.76 | 0.37 | 2.40% | 15.39 | 15.76 | 15.30 |
| Mar 26, 2024 | 15.47 | 0.45 | 3.00% | 15.02 | 15.81 | 15.02 |
| Mar 25, 2024 | 14.98 | -0.59 | -3.79% | 15.57 | 16.01 | 14.93 |
| Mar 22, 2024 | 15.52 | 0.55 | 3.67% | 14.97 | 15.79 | 14.94 |
| Mar 21, 2024 | 15.00 | 0.33 | 2.25% | 14.67 | 15.36 | 14.67 |
Day One Biopharmaceuticals Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 |
| Total Operating Expense | 146.909 | 72.743 | 13.782 | 14.905 |
| Selling/General/Admin. Expenses, Total | 61.291 | 29.159 | 4.682 | 1.006 |
| Research & Development | 85.618 | 43.584 | 9.1 | 13.899 |
| Operating Income | -146.909 | -72.743 | -13.782 | -14.905 |
| Interest Income (Expense), Net Non-Operating | 4.746 | 0.004 | -30.03 | -2.077 |
| Other, Net | -0.018 | -0.015 | -0.031 | -0.002 |
| Net Income Before Taxes | -142.181 | -72.754 | -43.843 | -16.984 |
| Net Income After Taxes | -142.181 | -72.754 | -43.843 | -16.984 |
| Minority Interest | 0 | -97.885 | 3.336 | 4.35 |
| Net Income Before Extra. Items | -142.181 | -170.639 | -40.507 | -12.634 |
| Net Income | -142.181 | -170.639 | -40.507 | -12.634 |
| Income Available to Common Excl. Extra. Items | -142.181 | -170.639 | -40.507 | -12.634 |
| Income Available to Common Incl. Extra. Items | -142.181 | -170.639 | -40.507 | -12.634 |
| Diluted Net Income | -142.181 | -170.639 | -40.507 | -12.634 |
| Diluted Weighted Average Shares | 65.4668 | 36.9606 | 60.3374 | 60.3374 |
| Diluted EPS Excluding Extraordinary Items | -2.1718 | -4.61678 | -0.67134 | -0.20939 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | ||
| Diluted Normalized EPS | -2.1718 | -4.61678 | -0.67134 | -0.20939 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 49.254 | 45.855 | 42.743 | 39.699 | 36.719 |
| Selling/General/Admin. Expenses, Total | 17.072 | 18.027 | 16.723 | 17.664 | 14.159 |
| Research & Development | 32.182 | 27.828 | 26.02 | 22.035 | 22.56 |
| Operating Income | -49.254 | -45.855 | -42.743 | -39.699 | -36.719 |
| Interest Income (Expense), Net Non-Operating | 3.406 | 3.466 | 2.66 | 1.895 | 0.189 |
| Other, Net | -0.015 | -0.004 | -0.026 | 0.009 | 0 |
| Net Income Before Taxes | -45.863 | -42.393 | -40.109 | -37.795 | -36.53 |
| Net Income After Taxes | -45.863 | -42.393 | -40.109 | -37.795 | -36.53 |
| Minority Interest | 0 | 0 | 0 | ||
| Net Income Before Extra. Items | -45.863 | -42.393 | -40.109 | -37.795 | -36.53 |
| Net Income | -45.863 | -42.393 | -40.109 | -37.795 | -36.53 |
| Income Available to Common Excl. Extra. Items | -45.863 | -42.393 | -40.109 | -37.795 | -36.53 |
| Income Available to Common Incl. Extra. Items | -45.863 | -42.393 | -40.109 | -37.795 | -36.53 |
| Diluted Net Income | -45.863 | -42.393 | -40.109 | -37.795 | -36.53 |
| Diluted Weighted Average Shares | 74.9649 | 71.9729 | 71.2988 | 71.009 | 60.7605 |
| Diluted EPS Excluding Extraordinary Items | -0.61179 | -0.58901 | -0.56255 | -0.53226 | -0.60121 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.61179 | -0.58901 | -0.56255 | -0.53226 | -0.60121 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|
| Total Current Assets | 347.874 | 289.368 | 45.071 | 27.339 |
| Cash and Short Term Investments | 342.269 | 284.309 | 43.728 | 27.332 |
| Cash | 85.262 | 284.309 | 43.728 | 27.332 |
| Prepaid Expenses | 5.605 | 5.059 | 1.343 | 0.007 |
| Total Assets | 349.062 | 289.821 | 45.661 | 27.339 |
| Total Current Liabilities | 16.615 | 8.657 | 1.996 | 2.021 |
| Accounts Payable | 0.26 | 1.744 | 0.202 | 0.069 |
| Accrued Expenses | 16.176 | 6.809 | 1.767 | 0.466 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.179 | 0.104 | 0.027 | 1.486 |
| Total Liabilities | 17.023 | 8.673 | 7.902 | 7.508 |
| Total Long Term Debt | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 5.702 | 5.487 | |
| Other Liabilities, Total | 0.408 | 0.016 | 0.204 | 0 |
| Total Equity | 332.039 | 281.148 | 37.759 | 19.831 |
| Redeemable Preferred Stock | 0 | 91.964 | 30.504 | |
| Common Stock | 0.007 | 0.006 | 2.637 | 2.111 |
| Retained Earnings (Accumulated Deficit) | -269.668 | -127.487 | -56.842 | -12.784 |
| Total Liabilities & Shareholders’ Equity | 349.062 | 289.821 | 45.661 | 27.339 |
| Total Common Shares Outstanding | 73.4582 | 61.9523 | 60.3374 | 60.3374 |
| Property/Plant/Equipment, Total - Net | 0.719 | 0.284 | 0.483 | |
| Property/Plant/Equipment, Total - Gross | 0.725 | 0.32 | 0.499 | |
| Accumulated Depreciation, Total | -0.006 | -0.036 | -0.016 | |
| Long Term Investments | 0.469 | 0.169 | 0.107 | |
| Additional Paid-In Capital | 601.771 | 408.629 | ||
| Short Term Investments | 257.007 | |||
| Other Equity, Total | -0.071 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 413.291 | 449.784 | 322.388 | 347.874 | 380.513 |
| Cash and Short Term Investments | 405.538 | 442.882 | 318.179 | 342.269 | 374.341 |
| Cash | 241.179 | 189.211 | 49.268 | 85.262 | 120.864 |
| Prepaid Expenses | 7.753 | 6.902 | 4.209 | 5.605 | 6.172 |
| Total Assets | 414.179 | 450.756 | 323.563 | 349.062 | 381.861 |
| Property/Plant/Equipment, Total - Net | 0.655 | 0.713 | 0.688 | 0.719 | 0.899 |
| Property/Plant/Equipment, Total - Gross | 0.685 | 0.731 | 0.7 | 0.725 | 0.982 |
| Accumulated Depreciation, Total | -0.03 | -0.018 | -0.012 | -0.006 | -0.083 |
| Long Term Investments | 0.233 | 0.259 | 0.487 | 0.469 | 0.449 |
| Total Current Liabilities | 24.475 | 24.512 | 22.848 | 16.615 | 18.271 |
| Accounts Payable | 3.391 | 4.565 | 4.657 | 0.26 | 3.973 |
| Accrued Expenses | 20.675 | 19.761 | 17.676 | 16.176 | 13.845 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.409 | 0.186 | 0.515 | 0.179 | 0.453 |
| Total Liabilities | 24.552 | 24.702 | 23.148 | 17.023 | 18.785 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | |||||
| Other Liabilities, Total | 0.077 | 0.19 | 0.3 | 0.408 | 0.514 |
| Total Equity | 389.627 | 426.054 | 300.415 | 332.039 | 363.076 |
| Redeemable Preferred Stock | |||||
| Common Stock | 0.009 | 0.009 | 0.007 | 0.007 | 0.007 |
| Retained Earnings (Accumulated Deficit) | -404.074 | -357.924 | -312.061 | -269.668 | -229.559 |
| Total Liabilities & Shareholders’ Equity | 414.179 | 450.756 | 323.563 | 349.062 | 381.861 |
| Total Common Shares Outstanding | 87.0429 | 86.9713 | 73.5726 | 73.4582 | 73.5119 |
| Additional Paid-In Capital | 793.699 | 783.978 | 612.402 | 601.771 | 593.02 |
| Short Term Investments | 164.359 | 253.671 | 268.911 | 257.007 | 253.477 |
| Other Equity, Total | -0.007 | -0.009 | 0.067 | -0.071 | -0.392 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|
| Net income/Starting Line | -142.181 | -72.754 | -43.843 | -16.984 |
| Cash From Operating Activities | -109.874 | -48.539 | -13.489 | -4.515 |
| Cash From Operating Activities | 0.063 | 0.02 | 0.016 | 0 |
| Non-Cash Items | 25.68 | 21.5 | 30.695 | 12.025 |
| Changes in Working Capital | 6.564 | 2.695 | -0.357 | 0.444 |
| Cash From Investing Activities | -255.074 | -8 | -0.092 | 0 |
| Capital Expenditures | -0.026 | 0 | -0.092 | 0 |
| Cash From Financing Activities | 165.901 | 297.12 | 29.977 | 30.905 |
| Financing Cash Flow Items | 0 | 0 | 1 | |
| Issuance (Retirement) of Stock, Net | 165.901 | 297.12 | 29.977 | 29.905 |
| Net Change in Cash | -199.047 | 240.581 | 16.396 | 26.39 |
| Other Investing Cash Flow Items, Total | -255.048 | -8 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -42.393 | -142.181 | -102.072 | -64.277 | -27.747 |
| Cash From Operating Activities | -25.985 | -109.874 | -74.564 | -51.35 | -21.563 |
| Cash From Operating Activities | 0.006 | 0.063 | 0.048 | 0.012 | 0.006 |
| Non-Cash Items | 8.931 | 25.68 | 19.681 | 12.007 | 6.249 |
| Changes in Working Capital | 7.471 | 6.564 | 7.779 | 0.908 | -0.071 |
| Cash From Investing Activities | -11.193 | -255.074 | -252.864 | -6.012 | -0.015 |
| Other Investing Cash Flow Items, Total | -11.167 | -255.048 | -252.838 | -5.99 | 0 |
| Cash From Financing Activities | 1.184 | 165.901 | 163.983 | 161.93 | 0 |
| Financing Cash Flow Items | 0 | 0 | |||
| Issuance (Retirement) of Stock, Net | 1.184 | 165.901 | 163.983 | 161.93 | 0 |
| Net Change in Cash | -35.994 | -199.047 | -163.445 | 104.568 | -21.578 |
| Capital Expenditures | -0.026 | -0.026 | -0.026 | -0.022 | -0.015 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
Leverage
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Day One Biopharmaceuticals Company profile
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.| Industry: | Biotechnology & Medical Research (NEC) |
2000 Sierra Point Parkway, Suite 501
BRISBANE
CALIFORNIA 94005
US
Income Statement
- Annual
- Quarterly
News
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024
Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com